Editorial Perspectives On Patient Recruitment

  1. Lupus Community Tackles Treatment & Clinical Trial Barriers 7/29/2019

    Few treatments have been approved for Lupus and the industry has seen many failed clinical trials. Variations in care worldwide, as well as poor overall access to care, has also hampered efforts to bring relief to patients. For those reasons, the international lupus community has come together to conduct a study aimed at identifying clinical and treatment barriers that must be overcome.

  2. The Cell Therapy Discovery About To Disrupt Clinical Trials 7/2/2019

    While pursuing hid PhD in chemical engineering at MIT, Armon Sharei developed an interest in novel cell therapies. That interest led him to a discovery that today is the foundation of SQZ Biotech, a cell-therapy company where he serves as CEO. Sharei discovered a new method of inserting materials into cells more effectively than anything that currently existed.

  3. 23andMe Wants To Solve The Patient Recruitment Problem 6/18/2019

    Developing cures for many diseases will require research into genetic data of the type 23andMe is collecting. The company is also collecting user information via voluntary surveys, asking users several questions every time they log on. The company now has, on average, over 350 data points (which 23andMe calls phenotypic information) on each customer. This information is helping the company match patients to trials.

  4. Humans And Machines Will Partner For Better Outcomes 6/3/2019

    Dr. Emmanuel Fombu spends a lot of time thinking about healthcare. He’s a trained physician and currently leads global strategy and digital innovation at Johnson & Johnson. He would like to see better roadmaps in healthcare that lead us to determining a patient’s level of health. Currently, your doctor asks a question, you supply an answer, and this begins the process of trying to figure out what might be wrong with you.  

  5. AI Speeds Patient Recruitment At Health Quest 5/23/2019

    Artificial intelligence (AI) has the potential to disrupt and revolutionize many aspects of clinical trials. One area in which it is already making an impact is patient recruitment. Mining electronic medical records (EMRs) for patients meeting inclusion and exclusion criteria can be tedious and time-consuming work but is a chore that seems ideal for an AI solution.

  6. Patient Centricity And Social Media Are Changing Patient Recruitment 4/18/2019

    Thirty years ago, patient recruitment was a challenge for pharma companies. Today the patient participation rate in trials still hovers around five percent and is not expected to improve anytime soon. Patient recruitment remains a challenge that pharma must work to overcome.  

  7. Alzheimer's Disease Trials: Where Do We Go From Here? 4/9/2019

    The Alzheimer’s disease space is not an easy one for pharma companies to navigate. In 2018 alone, Lundbeck, Takeda, Merck, Janssen, AstraZeneca, and Eli Lilly and Company all faced setbacks or poor trial results. Unfortunately, few spaces in the life sciences have fathered failure to the extent that experimental Alzheimer’s drugs have. 

  8. 4 Challenges To Overcome In Rare Disease Trials 3/28/2019

    Albireo Pharma is a clinical-stage biopharmaceutical company that was launched in 2008. One of the company’s more promising assets, A4250, is a novel bile acid modulator that has been in development for rare cholestatic liver diseases. The product, which acts locally in the gut, can effectively drain excess bile acids that get stuck in a patient’s liver. In conducting trials with pediatric patients in this space, Albireo faces four challenges common to developers of pediatric rare disease drugs.

  9. Fix Patient Recruitment By Learning From Service-Based Companies 3/7/2019

    How is the industry changing its perspective on patient recruitment? Maura Snyder, director of Clinical Insights and Experience at Janssen, shares some of her thoughts on the recruitment challenge and what pharma must do to overcome it. 

  10. How Academia, Physicians, And Patient Groups Will Impact Patient Recruitment 2/27/2019

    Thirty years ago, patient recruitment was a challenge for pharma companies. Today the patient participation rate in trials still hovers around five percent and is not expected to improve anytime soon. Mary Rose Keller, VP of Clinical Operations at Heron Therapeutics, shares some of her thoughts on the recruitment challenge and what pharma must do to overcome it.